Market Exclusive

Analyst Activity – Cowen and Company Reiterates Buy on Biogen (NASDAQ:BIIB)

Analyst Ratings For Biogen (NASDAQ:BIIB)

Today, Cowen and Company reiterated its Buy rating on Biogen (NASDAQ:BIIB).

There are 11 hold ratings, 13 buy ratings, 1 strong buy rating on the stock.

The current consensus rating on Biogen (NASDAQ:BIIB) is Buy (Score: 2.60) with a consensus target price of $331.23 per share, a potential 15.03% upside.

Some recent analyst ratings include

Recent Insider Trading Activity For Biogen (NASDAQ:BIIB)
Biogen (NASDAQ:BIIB) has insider ownership of 0.32% and institutional ownership of 87.50%.

Recent Trading Activity for Biogen (NASDAQ:BIIB)
Shares of Biogen closed the previous trading session at 287.95 down -7.66 -2.59% with 1,706,686 shares trading hands.

Exit mobile version